About US
Contact us
-
Indian watchdogs pull J&J plant's license on baby-powder sterilization issueJohnson & Johnson is busy negotiating with Asian regulators these days. As FiercePharma reported Friday, South Korean regulators forced the company to halt production at an over-the-counter drug2013/5/7
-
GSK monitored parents' online vaccination discussions for 2 monthsGlaxoSmithKline ($GSK) has been listening to parents' concerns about childhood vaccinations. Really listening. In fact, it has used big data analytics to sift through thousands of comments from Inter2013/5/6
-
J&J issue in South Korea reminiscent of OTC problems hereDrugmakers hope to export their success to emerging markets so they can reap big rewards, but Johnson & Johnson's ($JNJ) Janssen unit appears to have taken a backward approach in South Korea, whe2013/5/6
-
Sanofi taps new EVPs in commercial operations re-orgSanofi ($SNY) is rejigging its commercial operations, with two new executive vice presidents stepping up to the plate to replace the retiring global operations President Hanspeter Spek. Peter Guenter2013/5/3
-
CFDA issues the First Summary of Announcements of Illegal Drug, Medical Device, and Health Food Advertisements in 2013On April 19, 2013, China Food and Drug Administration (CFDA) issued the First Summary of Announcements of Illegal Drug, Medical Device, and Health Food Advertisements in 2013.2013/5/3
-
Even if Actavis buy fails, Valeant looks ready for bigger dealsValeant ($VRX) CEO J. Michael Pearson hasn't made a secret of his ambitions. He wants to be within spitting distance of Big Pharma. Numbers-wise, that means he's shooting for $10 billion in sales, qu2013/5/2
-
First patient treated with new drug for multiple myelomaA patient suffering with multiple myeloma has been treated with a human antibody drug in a phase II clinical trial of BI-505 from BioInvent International. The drug binds to the ICAM-1 adhesion protein2013/5/2
-
Sanofi distances itself from consultant caught up in tax fraud probeSanofi ($SNY), already facing intense criticism for job cuts in France, now finds itself defending the use of a lobbyist who was a consultant to CEO Chris Viehbacher. The company said it is no longer2013/4/27
-
Actavis to make generic tamper-resistant OxyContinPurdue Pharma and generic drugmaker Actavis ($ACT) have settled their patent suit over a special formulation of the painkiller OxyContin just 10 days the FDA banned generic versions that do not carry2013/4/27
-
New Bristol-Myers drug growth cushions plummeting Plavix salesBristol-Myers Squibb ($BMY) chose a good day to report its first-quarter results. AstraZeneca's ($AZN) declining sales and profits help blunt its own disappointments: earnings that dropped 44%, on a2013/4/26